תוצאות חיפוש - Audrey Koitka‐Weber

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME<sup>®</sup> trial

    Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME<sup>®</sup> trial מאת Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka‐Weber

    יצא לאור 2018
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  2. 2
    Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories

    Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories מאת Adeera Levin, Vlado Perkovic, David C. Wheeler, Stefan Hantel, Jyothis T. George, Maximilian von Eynatten, Audrey Koitka‐Weber, Christoph Wanner

    יצא לאור 2020
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

    Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial מאת Odette S. Reifsnider, M. Feldman, Christoph Wanner, Egon Pfarr, Audrey Koitka‐Weber, Sarah Brand, Matthew Stargardter, Cheng Wang, Effie Kuti, Anastasia Ustyugova

    יצא לאור 2021
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

    Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective o... מאת Gert Mayer, Christoph Wanner, Matthew R. Weir, Silvio E. Inzucchi, Audrey Koitka‐Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z.I. Cherney

    יצא לאור 2019
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

    Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure מאת Javed Butler, Faı̈ez Zannad, David Fitchett, Bernard Zinman, Audrey Koitka‐Weber, Maximilian von Eynatten, Isabella Zwiener, Jyothis T. George, Martina Brueckmann, Alfred K. Cheung, Christoph Wanner

    יצא לאור 2019
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  6. 6
    Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

    Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial מאת Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J.L. Heerspink

    יצא לאור 2020
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  7. 7
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function מאת Erik J.M. van Bommel, Yuliya Lytvyn, Bruce A. Perkins, Nima Soleymanlou, Nora Fagan, Audrey Koitka‐Weber, Jaap A. Joles, David Z.I. Cherney, Daniël H. van Raalte

    יצא לאור 2020
    קבל טקסט מלא
    Editorial
    הוספה למועדפים
    שמור ב:
  8. 8
    Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

    Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial מאת Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Silvio E. Inzucchi, Audrey Koitka‐Weber, Michaela Mattheus, Stefan Hantel, Hans‐Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Per‐Henrik Groop

    יצא לאור 2018
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  9. 9
    Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

    Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOM... מאת Bettina J. Kraus, Matthew R. Weir, George L. Bakris, Michaela Mattheus, David Z.I. Cherney, Naveed Sattar, Hiddo J.L. Heerspink, Ivana Ritter, Maximilian von Eynatten, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Audrey Koitka‐Weber

    יצא לאור 2020
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  10. 10
    Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp>‐<scp>T2D</scp> trial

    Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp>‐<scp>T2D</scp> trial מאת Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, Berthold Hocher, Keizo Kanasaki, Masakazu Haneda, Guntram Schernthaner, Kumar Sharma, Robert C. Stanton, Robert D. Toto, Jessica Cescutti, Maud Gordat, Thomas Meinicke, Audrey Koitka‐Weber, Sandra Thiemann, Maximilian von Eynatten

    יצא לאור 2017
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  11. 11
    International consensus definitions of clinical trial outcomes for kidney failure: 2020

    International consensus definitions of clinical trial outcomes for kidney failure: 2020 מאת Adeera Levin, Rajiv Agarwal, William G. Herrington, Hiddo J.L. Heerspink, Johannes F.E. Mann, Shahnaz Shahinfar, Katherine R. Tuttle, Jo-Ann Donner, Vivekanand Jha, Masaomi Nangaku, Dick de Zeeuw, Meg Jardine, Kenneth W. Mahaffey, Aliza M. Thompson, Mary Beaucage, Kate Chong, Glenda V. Roberts, Duane Sunwold, Hans Vorster, Madeleine Warren, Sandrine Damster, Charu Malik, Vlado Perkovic, Shuchi Anand, Nicholas B. Argent, Elena Babak, Debasish Banerjee, Jonathan Barratt, Aminu K. Bello, Angelito A. Bernardo, Jaime D. Blais, William Canovatchel, Fergus Caskey, Josef Coresh, Ian H. de Boer, Kai‐Uwe Eckardt, Rhys Evans, Harold I. Feldman, Agnes B. Fogo, Hrefna Guðmundsdóttir, Takayuki Hamano, David C.H. Harris, Sibylle J. Hauske, Richard Haynes, Charles A. Herzog, Thomas F. Hiemstra, Thomas Idorn, Lesley A. Inker, Julie H. Ishida, David W. Johnson, Charlotte Jones-Burton, Amer Joseph, Audrey Koitka‐Weber, Matthias Kretzler, Robert Lawatscheck, Adrian Liew, Louise Moist, Saraladevi Naicker, Reiko Nakashima, Uptal D. Patel, Roberto Pecoits–Filho, Jennifer B. Rose, Noah L. Rosenberg, Marvin Sinsakul, William E. Smoyer, Laura Solá, Amy R. Sood, Bénédicte Stengel, Maarten W. Taal, Mototsugu TANAKA, Marcello Tonelli, Allison Tong, Robert Toto, Michele Trask, Ifeoma Ulasi, Christoph Wanner, David C. Wheeler, Benjamin Ole Wolthers, Harold M. Wright, Yoshihisa Yamada, Elena Zakharova

    יצא לאור 2020
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: